Natco Pharma Ka Sasta Injection: Diabetes Patients Ki Hui Mauj! Ab Ilaaj Sirf ₹1,290/Month Mein

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorRiya Kapoor|Published at:
Natco Pharma Ka Sasta Injection: Diabetes Patients Ki Hui Mauj! Ab Ilaaj Sirf ₹1,290/Month Mein
Overview

Bhaiyo, Natco Pharma ne diabetes ke liye jo semaglutide injection launch kiya hai na, woh ekdum sasta hai! Sirf **₹1,290** per month mein mil raha hai, matlab innovator drug se **70%** tak sasta. Patients ke liye ye ekdum badhiya news hai.

Saste Price Par Launch Ka Asar

Asal mein, jo original semaglutide drug ka patent khatam hua hai, usi ka fayda utha kar Natco Pharma ne apna generic version market mein laya hai. Company ka target hai ki zyada se zyada patients iska fayda utha payein. Isliye, inki multi-dose vials, jinhe SEMANAT aur SEMAFULL naam se becha ja raha hai, unki price sirf ₹1,290 prati mahina hai. Ye pehle se available pen devices se 70% aur original branded medicine se lagbhag 90% tak kam hai.

CDSCO Approval Aur Aage Kya?

Natco Pharma ko February 2026 mein hi Central Drugs Standard Control Organisation (CDSCO) se is product ko banane aur bechne ki permission mil gayi thi. Aur suno, company April 2026 mein ek pen device version bhi launch karne ka plan kar rahi hai, jiska price around ₹4,000 se ₹4,500 ke beech ho sakta hai. Matlab, har tarah ke patient ke liye option available hoga.

Investors Khush, Share Bhaag Gaya!

Natco Pharma ke is launch ko dekh kar market ne bhi positive response diya hai. Company ke shares 3.20% bhag gaye aur ₹968.10 ke level par pahunch gaye. Ye dikhata hai ki investors ko Natco Pharma ke product launches aur patent expiry ka fayda uthane ki strategy par full bharosa hai. Hal hi mein company ne US mein bhi Breckenridge Pharmaceutical ke saath milkar Celgene ke Pomalyst ka generic version launch kiya tha.

Disclaimer:This content is for informational purposes only and does not constitute financial or investment advice. Readers should consult a SEBI-registered advisor before making decisions. Investments are subject to market risks, and past performance does not guarantee future results. The publisher and authors are not liable for any losses. Accuracy and completeness are not guaranteed, and views expressed may not reflect the publication’s editorial stance.